<DOC>
	<DOCNO>NCT02586311</DOCNO>
	<brief_summary>Trial Evaluate Efficacy Safety CKD-330 versus Amlodipine Monotherapy Hypertensive Patients Inadequately Controlled Amlodipine Monotherapy</brief_summary>
	<brief_title>CKD-330 Phase 3 Trial Amlodipine Non-responder</brief_title>
	<detailed_description>A Randomized , Double-blind , Multi-center , Phase 3 Trial Evaluate Efficacy Safety CKD-330 versus Amlodipine Monotherapy Hypertensive Patients Inadequately Controlled Amlodipine Monotherapy</detailed_description>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Age 19 Essential hypertension 140mmHg ≤ mean sitSBP &lt; 180mmHg target arm Visit 2 Ability provide write informed consent The difference arm sitSBP ≥ 20mmHg and/or sitDBP ≥ 10mmHg Visit 1 mean sitSBP ≥ 200mmHg and/or mean sitDBP ≥ 120mmHg target arm Visit 1 mean sitSBP ≥ 180mmHg and/or mean sitDBP ≥ 120mmHg target arm Visit 2 Known suspect Secondary Hypertension Type I Diabetes Mellitus Type II Diabetes Mellitus HbA1c &gt; 9 % Patients severe congestive heart failure ( NYHA class III , IV ) Patient ischemic heart disease , Ischemic cardiovascular disease , Valvular heart disease , arrhythmia require treatment within 3 month History cerebrovascular disease cerebral infarction , cerebral hemorrhage within 6 month History severe malignant retinopathy AST/ALT ≥ UNL*3 , Serum creatinine ≥ UNL*1.5 , K &gt; 5.5mEq/L Patients acute chronic inflammatory status require treatment Patient need take antihypertensive drug besides Investigational product Patient must treat medication prohibit concomitant use study period History angioedema relate ACE inhibitor angiotensin II receptor blocker History disability drug ADME , active inflammatory bowel syndrome within 12months , impair pancreatic function , GI bleeding , obstruction urinary tract History malignant tumor within 5 year Patient dependent drug alcohol within 6 month Hypersensitive Candesartan/Amlodipine Women pregnant , breastfeed Patients treated investigational product within 30 day first time take investigational product Not eligible participate study discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>